| Contact Us Home |
|
|
|
|
|
|
|
|
|
 |
2007 Presentations
Available Presentations are underlined.
Sixth Annual Advocacy Forum: Intellectual Property & Therapeutics Development
Overview of Intellectual Property Law – What Are The Driving Forces for Today’s Drug Developers?
Chief Judge Elect, The Honorable David Gersten;
Third District Court of Appeals, Miami, FL
NIH and the Role of Federal Funding in the Generation of Intellectual Property
Mark Rohrbaugh,PhD, Director NIH Office of Technology Transfer; Rockville, MD
Academic Institutions as Generators, Holders and Transferors of IP
Michael Cleare, PhD, Executive Director, Science and Technology Ventures, Columbia University New York, NY
Accelerating Therapeutics Development – A New Vision
Robi Blumenstein, President, MRSSI and Senior Advisor to the High Q Foundation, New York, NY
Fundamentals of Clinical Trials in Neurotherapeutics
Introduction: Stages of Therapeutic Development
Roger J. Porter, M.D.
Nonclinical Studies
Eric Siemers, M.D., Eli Lilly & Company
Trial Design – Early Development
Karl Kieburtz, M.D., Professor of Neurology, University of Rochester
Trial Design – Late Development
John Marler, M.D., NIH
Alternative Trial Designs - Presentation is not available
Michael Krams, M.D., Wyeth
Barbara Tilley, Ph.D., Medical University of South Carolina
Ethics of Clinical Trials
Ira Shoulson, M.D., Professor, University of Rochester
Lucinda Wilson, Prestwick Pharmaceuticals
Kenneth W. Sommerville M.D., Vice President of Medical Therapeutics, Schwarz Biosciences
Symposium: Ion Channels as Targets for Neurotherapeutics Development
Profiling Human Ion Channel Gene Variation - Presentation is not available
Jeffrey Noebels, M.D., Ph.D., Baylor College of Medicine
Sodium and Calcium Channels
William Catterall, Ph.D., University of Washington
KCNQ Potassium Channels: Drug Targets for the Treatment of Epilepsy and Pain
Gregory C. Rigdon, Ph.D., Icagen, Inc.
Nicotinic Receptors in Nicotine Addiction and Parkinson's Disease
Henry Lester, Ph.D., California Institute of Technology
Targeting Voltage-gated Calcium Channels in Central and Peripheral Nociceptive Pathways
Terrance P. Snutch, PhD, FRSC, University of British Columbia & Neuromed Pharmaceuticals Inc.
Workshop: Disease Specific Clinical Trial Think Tanks
Stroke
Marc Fisher, M.D. (STAIR)
Jackie French, M.D. (AED IX)
Pain
John Farrar, M.D., Ph.D. (IMMPACT)
Michael F. Green, PhD, (MATRICS)
FDA Collaboration with Neurologic Specialties Through Interactive Clinical Trial Meetings
Robert Rappaport, M.D., Center for Drug Evaluation and Research, FDA
Workshop: Neuroethics
Ethics 2007
The Honorable David Gersten, Third District Court of Appeals, Miami, FL
A Brief History of Conflict of Interest in Research
Roger J. Porter, M.D.
Justifying the Risks of Research
Jason Karlawish, M.D., University of Pennsylvania
Ethics of Surrogate Consent for Research
Scott Kim, M.D., Ph.D., University of Michigan
Russell Katz, M.D., FDA
Dinner Symposium: Neurologic Therapeutics in Pediatrics
The State of Clinical Pediatric Trials in the United States
Edward Kaye, M.D., Vice President of Clinical Research, Genzyme Corporation
The State of Clinical Pediatric Trials in Europe
Virinder Nohria,M.D., Ph.D.
The NIH Contribution to Clinical Trials in the US
Anne Zajicek, M.D., Senior Program Officer, NICHD, NIH
The Pediatric Rule--How It Succeeds and How It Fails
Russell Katz, M.D., Director of Neuropharmacology, FDA
Symposium: Sleep and Neurotherapeutics
Basic Mechanisms of Sleep Click Here to view article
Clifford Saper, M.D., Ph.D., Beth Israel Hospital
Beth Malow, M.D., M.S., Vanderbilt University
Parkinson's Disease and Sleep
David Rye, M.D., Ph.D., Emory University Hospital
Treatments for Sleep Disorders: Regulatory Challenges and Standards of Evidence
Russell Katz, M.D., Director of Neuropharmacology, FDA
